Madrigal Pharmaceuticals Announces Publication in The Lancet of Positive Phase 2 Results for Resmetirom (MGL-3196) for the Treatment of Non-alcoholic Steatohepatitis (NASH)November 11, 2019
Madrigal Pharmaceuticals Reports 2019 Third Quarter ResultsNovember 6, 2019
Madrigal Pharmaceuticals Reports 2019 Second Quarter ResultsAugust 7, 2019
Press Release History
Website Developed by Alan Leff Associates, Inc.